Ocular Therapeutix (OCUL) Adds to DEXTENZA NDA Gains

August 5, 2016 10:36 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Ocular Therapeutix (NASDAQ: OCUL) is adding to yesterday's 34 percent move higher today, with shares up around 10 percent.

Yesterday, Ocular provided an update on the status of its New Drug Application (NDA) for DEXTENZA (dexamethasone insert) 0.4 mg, for intracanalicular use in the treatment of ocular pain occurring after ophthalmic surgery.

Earlier today, Ocular announced that Jonathan Talamo, M.D., Chief Medical Officer, will present at the Ophthalmology Innovation Summit (OIS) at the American Society of Retina Specialists (ASRS) on Monday, August 8, 2016, in San Francisco, CA.

Dr. Talamo will provide an update on the Company’s ongoing preclinical development programs for its sustained release hydrogel technology being developed to treat wet age-related macular degeneration (wet AMD) and other retinovascular diseases. The Company is developing sustained-release hydrogel-based drug delivery depots for intravitreal injection that can be formulated with both small and large molecule pharmaceuticals, with the goal of delivering sustained and therapeutic levels of drugs to targeted ocular tissues for 4-6 months.

“We at Ocular Therapeutix continue to be encouraged by the results emerging from work with our proprietary delivery platforms for high molecular weight protein VEGF inhibitors and small molecule Tyrosine Kinase Inhibitors,” stated Dr. Talamo. “I look forward to sharing these interesting findings with my colleagues in San Francisco next week.”

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Momentum Movers, Trader Talk

Add Your Comment